Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Bora Pharmaceuticals Co's 5-Year RORE % for the quarter that ended in Dec. 2025 was 25.31%.
The industry rank for Bora Pharmaceuticals Co's 5-Year RORE % or its related term are showing as below:
TPE:6472's 5-Year RORE % is ranked better than 77.56% of 878
companies
in the Drug Manufacturers industry
Industry Median: 1.35
vs TPE:6472: 25.31
Bora Pharmaceuticals Co (TPE:6472) 5-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Bora Pharmaceuticals Co 5-Year RORE % Related Terms
Bora Pharmaceuticals Co 5-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co 5-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 5-year before.
Bora Pharmaceuticals Co (TPE:6472) has a 5-Year RORE % of 25.31 as of Dec. 2025. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Bora Pharmaceuticals Co and its competitors. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #197 out of 878 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is Bora Pharmaceuticals Co's 5-Year RORE % too high?
Bora Pharmaceuticals Co's current 5-Year RORE % is 25.31. The Drug Manufacturers industry median 5-Year RORE % is 1.35. Bora Pharmaceuticals Co's value of 25.31 is 1774.8% above this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #197 out of 878 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bora Pharmaceuticals Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's 5-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #197 out of 878 companies for 5-Year RORE %. This places Bora Pharmaceuticals Co in the top 22% of its industry — outperforming the majority of peers. The industry median 5-Year RORE % is 1.35. Bora Pharmaceuticals Co's value of 25.31 is 1774.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Drug Manufacturers company?
The median 5-Year RORE % among Drug Manufacturers companies is 1.35, based on 878 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current 5-Year RORE % of 25.31 is 1774.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 5-Year RORE % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current 5-Year RORE % is 25.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$736.58, compared to a current price of NT$396.00 — trading 46.2% below its estimated fair value. The current 5-Year RORE % is 25.31 and 1774.8% above the Drug Manufacturers industry median of 1.35. Bora Pharmaceuticals Co's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current 5-Year RORE % is 25.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$396.00 is trading 46.2% below its estimated GF Value™ of NT$736.58.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
5-Year RORE %: 25.31
GF Value™: NT$736.58 vs. price of NT$396.00 (46.2% below fair value)
Industry Position: 1774.8% above the Drug Manufacturers median (#197 of 878)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
83GF Score
Get the complete analysis for TPE:6472
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
